CoChat
Sign Up
Cited by 18Ocular Surface and Contact LensDermatology and Skin DiseasesContact Dermatitis and Allergies

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review

Open access
Shi, Vivian Y., Chamberlain, Winston, Siegfried, Elaine, Kraff-Cooper, Cheryl, Beckman, Kenneth, Lio, Peter, Paller, Amy S., Simpson, Eric·2023·Journal of the American Academy of Dermatology
DOI 10.1016/j.jaad.2023.01.043
Open this paper in CoChat — free accountOpen PDF

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that can significantly decrease quality of life. AD is commonly associated with comorbidities including ocular surface disease (OSD). Conjunctivitis is the most common OSD associated with AD and can increase in incidence with use of monoclonal antibody biologics that target the type 2 inflammatory pathway. The objective of this review is to raise awareness of comorbid OSD in AD patients that dermatologists may encounter, with a focus on conjunctivitis, and equip dermatologists to address mild ocular concerns. We provide background on the subtypes and pathogenesis of comorbid OSD in AD patients and describe OSD associated with type 2 inflammation-inhibiting AD biologics. We also discuss screening and diagnosis, recommended treatment options for dermatologists, and when to refer to an eye care specialist. This multispecialty approach aims to support the overall health of AD patients and provide optimal patient care.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2023.01.043

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment with anti-IL-4/IL-13 biologicals is associated with conjunctival inflammation, especially after three months of dupilumab use, in a restricted number of adult patients (6%-30%), especially when high basal serum TARC and total IgE are observed.

    “Treatment with anti-IL-4/IL-13 biologicals is associated with conjunctival inflammation, especially after three months of dupilumab use, in a restricted number of adult patients (6%–30%), which occurs especially when high basal serum levels of Thymus and Activation-Regulated Chemokine / CCL17 (TARC) and total IgE are observed.”

    From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [16]

    The Immunopathogenesis section reports that adult patients with atopic dermatitis who developed conjunctivitis during dupilumab treatment had high baseline serum TARC and IgE. The Recognition section associates biologic treatment with conjunctivitis, but says onset can range from two weeks to a year; our copy does not establish that it occurs especially after three months or give the claimed 6%–30% rate. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • The immunopathogenic mechanism of OSD involves adaptive T-cell immunity against allergens or pathogens on the ocular surface.

    “The immunopathogenic mechanism involves adaptive T-cell immunity against allergens or pathogens on the ocular surface.”

    From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [16]

    The Immunopathogenesis section says that the proposed mechanism of allergic conjunctivitis involves adaptive, T-cell-mediated immunity against allergens or pathogens on the ocular surface. The claim extends that proposed mechanism to ocular surface disease generally, although the Introduction identifies several other OSD conditions. The supplied passages do not give page numbers. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • Between 25% and 50% of patients with severe AD (OR=2.17), asthma and rhinitis (OR=1.76), and childhood-onset AD (OR=1.34) are associated with OSD.

    “Between 25% and 50% of patients with severe AD (Odds Ratio [OR = 2.17]), asthma and rhinitis (OR = 1.76), and childhood-onset AD (OR = 1.34) are associated with OSD.”

    From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [16]

    The Introduction reports a historical OSD estimate of 25%–50% among patients with AD and gives the three stated odds ratios as risk factors for OSD. It does not limit the 25%–50% estimate to patients with severe AD; severity is a separate risk factor. (LLM, conf=0.91)

    Experimental — accuracy not yet measured

  • AD is associated with Ocular Surface Disease (OSD).

    “AD is also associated with Ocular Surface Disease (OSD).”

    From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [16]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 44

  1. Avena-Woods, 2017, Overview of atopic dermatitis, Am J Manag Care, 23, S115
  2. Wu, 2021, Association between atopic dermatitis and conjunctivitis in adults: a population-based study in the United States, J Dermatolog Treat, 32, 455, 10.1080/09546634.2019.1659480 · DOI
  3. Pietruszyńska, 2020, Ophthalmic manifestations of atopic dermatitis, Postepy Dermatol Alergol, 37, 174, 10.5114/ada.2018.79445 · DOI
  4. Achten, 2022, Ocular surface disease is common in moderate-to-severe atopic dermatitis patients, Clin Exp Allergy, 52, 801, 10.1111/cea.14127 · DOI
  5. Ronnstad, 2022, Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey, J Eur Acad Dermatol Venereol, 36, 592, 10.1111/jdv.17832 · DOI
  6. Gooderham, 2018, Diagnosis and management of conjunctivitis for the dermatologist, J Cutan Med Surg, 22, 200, 10.1177/1203475417743233 · DOI
  7. Patel, 2018, Ocular involvement in atopic disease: a review, Curr Opin Ophthalmol, 29, 576, 10.1097/ICU.0000000000000532 · DOI
  8. Azari, 2020, Conjunctivitis: a systematic review, J Ophthalmic Vis Res, 15, 372, 10.18502/jovr.v15i3.7456 · DOI
  9. Treister, 2018, Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis, JAMA Dermatol, 154, 1208, 10.1001/jamadermatol.2018.2690 · DOI
  10. Thyssen, 2019, Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion, J Eur Acad Dermatol Venereol, 33, 1224, 10.1111/jdv.15608 · DOI
  11. Halling, 2021, Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis, J Am Acad Dermatol, 84, 139, 10.1016/j.jaad.2020.08.051 · DOI
  12. Agnihotri, 2019, A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis, Drugs R D, 19, 311, 10.1007/s40268-019-00288-x · DOI
  13. Wollenberg, 2022, Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials, Br J Dermatol, 186, 453, 10.1111/bjd.20810 · DOI
  14. Miyazaki, 2020, Epidemiological aspects of allergic conjunctivitis, Allergol Int, 69, 487, 10.1016/j.alit.2020.06.004 · DOI
  15. Thyssen, 2017, Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis, J Am Acad Dermatol, 77, 280, 10.1016/j.jaad.2017.03.003 · DOI
  16. Kenny, 2020, Giant papillary conjunctivitis: a review, Ocul Surf, 18, 396, 10.1016/j.jtos.2020.03.007 · DOI
  17. Borkar, 2014, Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study, JAMA Ophthalmol, 132, 326, 10.1001/jamaophthalmol.2013.6277 · DOI
  18. Guglielmetti, 2010, Atopic keratoconjunctivitis and atopic dermatitis, Curr Opin Allergy Clin Immunol, 10, 478, 10.1097/ACI.0b013e32833e16e4 · DOI
  19. Ratnarajah, 2021, Inhibition of IL-13: a new pathway for atopic dermatitis [formula: see text], J Cutan Med Surg, 25, 315, 10.1177/1203475420982553 · DOI
  20. Niederkorn, 2008, Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models, Curr Opin Allergy Clin Immunol, 8, 472, 10.1097/ACI.0b013e32830edbcb · DOI
  21. Junttila, 2018, Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes, Front Immunol, 9, 888, 10.3389/fimmu.2018.00888 · DOI
  22. Berger, 2002, IL-4 and IL-13 regulation of ICAM-1 expression and eosinophil recruitment in Onchocerca volvulus keratitis, Invest Ophthalmol Vis Sci, 43, 2992
  23. Liu, 2020, Sympathetic nerves positively regulate eosinophil-driven allergic conjunctivitis via alpha1-adrenergic receptor signaling, Am J Pathol, 190, 1298, 10.1016/j.ajpath.2020.02.004 · DOI
  24. Bielory, 2010, Atopic dermatitis and keratoconjunctivitis, Immunol Allergy Clin North Am, 30, 323, 10.1016/j.iac.2010.06.004 · DOI
  25. Bakker, 2021, Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: a case series study, Allergy, 76, 3814, 10.1111/all.15064 · DOI
  26. Uchida, 2020, Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting, J Am Acad Dermatol, 82, 1247, 10.1016/j.jaad.2019.12.039 · DOI
  27. Bakker, 2019, Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis, Br J Dermatol, 180, 1248, 10.1111/bjd.17538 · DOI
  28. Garcia-Posadas, 2018, Context-dependent regulation of conjunctival goblet cell function by allergic mediators, Sci Rep, 8, 12162, 10.1038/s41598-018-30002-x · DOI
  29. Hansen, 2022, IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro, Allergy, 77, 2555, 10.1111/all.15326 · DOI
  30. Thompson, 2021, Dermatology-ophthalmology collaborations are needed in dupilumab-associated ocular events, J Am Acad Dermatol, 84, e279, 10.1016/j.jaad.2021.01.043 · DOI
  31. Ravn, 2021, Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis, J Am Acad Dermatol, 85, 453, 10.1016/j.jaad.2020.11.037 · DOI
  32. Chan, 2022, A systematic review of clinical practice guidelines for infectious and non-infectious conjunctivitis, Ophthalmic Epidemiol, 29, 473, 10.1080/09286586.2021.1971262 · DOI
  33. Calabrese, 2021, Dupilumab and conjunctivitis: a case series of twenty patients, J Eur Acad Dermatol Venereol, 35, e612, 10.1111/jdv.17210 · DOI
  34. Baudouin, 2010, Preservatives in eyedrops: the good, the bad and the ugly, Prog Retin Eye Res, 29, 312, 10.1016/j.preteyeres.2010.03.001 · DOI
  35. Periman, 2020, The immunological Basis of dry eye disease and current topical treatment options, J Ocul Pharmacol Ther, 36, 137, 10.1089/jop.2019.0060 · DOI
  36. Ricketti, 2015, Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease, Allergy Asthma Proc, 36, 123, 10.2500/aap.2015.36.3827 · DOI
  37. de Bruin-Weller, 2018, Br J Dermatol, 178, 1083, 10.1111/bjd.16156 · DOI
  38. Simpson, 2020, Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial, JAMA Dermatol, 156, 44, 10.1001/jamadermatol.2019.3336 · DOI
  39. Thaci, 2019, Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2), J Dermatol Sci, 94, 266, 10.1016/j.jdermsci.2019.02.002 · DOI
  40. Mennini, 2017, Two phase 3 trials of dupilumab versus placebo in atopic dermatitis, N Engl J Med, 376, 1090, 10.1056/NEJMc1700366 · DOI
  41. Bortoluzzi, 2022, New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab, Br J Dermatol, 186, 186, 10.1111/bjd.20706 · DOI
  42. Bohner, 2021, Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up, Cornea, 40, 584, 10.1097/ICO.0000000000002461 · DOI
  43. Levine, 2018, Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management, JAMA Dermatol, 154, 1485, 10.1001/jamadermatol.2018.3427 · DOI
  44. Lee, 2017, Vision and public health: framing a purpose for Our work, Ophthalmology, 124, 148, 10.1016/j.ophtha.2016.11.003 · DOI

Cited by

Sorted by citations

Metadata

Authors
Shi, V. Y., Chamberlain, W., Siegfried, E., Kraff-Cooper, C., Beckman, K., Lio, P., Paller, A. S., & Simpson, E.
Affiliations
  • University of Arkansas for Medical Sciences (US)
  • Oregon Health & Science University (US)
  • Cardinal Glennon Children’s Medical Center (US)
  • Kraff Eye Institute (US)
  • The Ohio State University (US)
  • Northwestern University (US)
Corresponding author
Shi, Vivian Y.
ORCID
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2023-08
Volume
89
Issue
2
Pages
309-315
ISSN
0190-9622 (ISSN-L)
DOI
10.1016/j.jaad.2023.01.043
OpenAlex
W4320921261
Cited by
18
References
4
Citations by year
2026: 2 · 2025: 10 · 2024: 4 · 2023: 2
FWCI
0.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American Academy of Dermatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Eczema Association
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Celgene
  • Regeneron Pharmaceuticals
  • Valeant Pharmaceuticals International
  • Les Laboratories Pierre Fabre
  • Dermira
  • Kowa Company
  • Kiniksa Pharmaceuticals
  • Incyte
  • Ortho Dermatologics
  • Castle Biosciences
  • Galderma
  • Sun Pharma
  • LEO Pharma
  • Allergan
  • Sanofi Genzyme
Topics
  • Health Sciences › Medicine › Ophthalmology › Ocular Surface and Contact Lens
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords
atopic dermatitis, ocular surface disease, conjunctivitis, comorbidities, type 2 inflammation, vision screening, ocular surface disease treatment, referral to ophthalmologist
MeSH terms
Conjunctivitis, Dermatitis, Atopic, Eye Diseases, Humans, Inflammation, Quality of Life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review